Intestinal secretion of intravenous talinolol is inhibited by luminal R- verapamil

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 3, 1999, Pages 239-245

  Gramatté, Thomas ^a,b   Oertel, Reinhard ^c  

^a APOGEPHA Arzneimittel GmbH   (Germany)

^b APOGEPHA Arzneimittel GmbH   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DEXVERAPAMIL; GLYCOPROTEIN P; TALINOLOL;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG TRANSPORT; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTESTINE PERFUSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SMALL INTESTINE ABSORPTION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTI-ARRHYTHMIA AGENTS; BIOLOGICAL AVAILABILITY; CALCIUM CHANNEL BLOCKERS; DRUG INTERACTIONS; HUMANS; INFUSIONS, INTRAVENOUS; INTESTINAL ABSORPTION; INTESTINES; MALE; PROPANOLAMINES; REFERENCE VALUES; VASODILATOR AGENTS; VERAPAMIL; VOLUNTARY WORKERS;

EID: 0032823160     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70031-7     Document Type: Article

References (26)

1. 1. Gramatté T, Oertel R, Terhaag B, Kirch W. Direct demonstration of small intestinal secretion and site-dependent absorption of the β-blocker talinolol in humans. Clin Pharmacol Ther 1996;59:541-9.
2. 2. Wetterich U, Spahn-Langguth H, Mutschler E, Terhaag B, Rösch W, Langguth P. Evidence for intestinal secretion as additional clearance pathway of talinolol enantiomers: Concentration-and dose-dependent absorption in vitro and in vivo. Pharm Res 1996;13:514-22.
3. 3. Spahn-Langguth H, Baktir G, Radschuweit A, Okyar A, Terhaag B, Ader A, et al. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int J Clin Pharmacol Ther 1998;36: 16-24.
4. 4. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-62.
5. 5. Karlsson J, Kuo SM, Ziemniak J, Artursson P. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br J Pharmacol 1993;110: 1009-16.
6. 6. Trausch B, Oertel R, Richter K, Gramatté T. Disposition and bioavailability of the β-adrenoceptor antagonist talinolol in man. Biopharm Drug Dispos 1995;16:403-14.
7. 7. Cooper H, Levitan R, Fordtran JS, Ingelfinger FJ. A method for studying absorption of water and solute from the human small intestine. Gastroenterology 1966; 50:1-7.
8. 8. Gramatté T, El Desoky E, Klotz U. Site-dependent small intestinal absorption of ranitidine. Eur J Clin Pharmacol 1994;46:253-9.
9. 9. Gramatté T, Richter K. Paracetamol absorption from different sites in the human small intestine. Br J Clin Pharmacol 1994;37:608-11.
10. 10. Fordtran JS, Rector FC, Ewton MF, Soter N, Kinney J. Permeability characteristics of the human small intestine. J Clin Invest 1965;44:1935-44.
11. 11. Oertel R, Richter K, Trausch B, Berndt A, Gramatté T, Kirch W. Elucidation of the structure of talinolol metabolites in man: determination of talinolol and hydroxylated talinolol metabolites in urine and analysis of talinolol in serum. J Chromatogr 1994;660:353-63.
12. 12. Oertel R, Richter K, Berndt A, Gramatté T, Kirch W. Stereoselective high-performance liquid chromatographic assay for propranolol and for talinolol enantiomers after chiral derivatization. Eur J Clin Pharmacol 1996;50:551.
13. 13. Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, Eichelbaum M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1993;348:332-7.
14. 14. Malawer SJ, Powell DW. An improved turbidimetric analysis of polyethylene glycol utilizing an emulsifier. Gastroenterology 1967;53:250-6.
15. 15. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia, in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41:1967-72.
16. 16. Echizen H, Brecht T, Niedergesäss S, Vogelgesang B, Eichelbaum M. The effect of dextro-, levo-and racemic-verapamil on atrioventricular conduction in man. Am Heart J 1985;109:210-7.
17. 17. Häussermann K, Benz B, Gekeler V, Schumacher K, Eichelbaum M. Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines. Eur J Clin Pharmacol 1991;40:53-9.
18. 18. Noviello E, Allievi E, Russo P, Parodi S. Effects of dex-verapamil on doxorubicin cytotoxicity in P388 murine leukemia cells. Anticancer Drug Des 1997;12: 2261-76.
19. 19. Trausch B, Oertel R, Richter K, Gramatté T. Die Protein-bindung von Talinolol. Pharmazie 1995;50:72.
20. 20. Hogben CAM, Tocco DJ, Brodie BB, Schanker LS. On the mechanism of intestinal absorption of drugs. J Pharmacol Exp Ther 1959;125:275-82.
21. 21. Turner RH, Mehta CS, Benet LZ. Apparent directional permeability coefficients for drug ions: in vitro intestinal perfusion studies. J Pharm Sci 1970;59:590-5.
22. 22. Rowland M, Douglas KT, Warhust G. Paracellular permeation. Eur J Pharmacol Sci 1997;5(suppl 2):S22-3.
23. 23. Terhaag B, Gramatté T, Richter K, Voss J, Feller K. The biliary elimination of the selective beta receptor blocking drug talinolol in man. Int J Clin Pharmacol Ther Toxicol 1989;27:170-2.
24. 24. Sandström R, Karlsson A, Knutson L, Lennernäs H. Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm Res 1998;15:856-62.
25. 25. Schwarz UI, Gramatté T, Krappweis J, Berndt A, Oertel R, von Richter O, et al. Unexpected effect of verapamil on oral bioavailability of the β-blocker talinolol in humans. Clin Pharmacol Ther 1999;65:283-90.
26. 26. Duennebier D. Zum Einfluss der gastrointestinalen Motilität auf die orale Pharmakokinetik von Talinolol bei gesunden Probanden [Thesis]. Dresden, Germany: University of Technology Dresden, Medical School; 1998. p. 37-9.